Last Updated: November 16, 2026

Investigational Drug Information for Seviteronel

« Back to Dashboard


What is the development status for investigational drug Seviteronel?

Seviteronel is an investigational drug.

There have been 6 clinical trials for Seviteronel. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2015.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Triple Negative Breast Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are Innocrin Pharmaceutical, St Vincent's Hospital, Sydney, and National Cancer Institute (NCI).

Recent Clinical Trials for Seviteronel
TitleSponsorPhase
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast CancerSt Vincent's Hospital, SydneyPhase 1/Phase 2
Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive GlioblastomaSt Vincent's Hospital, SydneyPhase 2
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)Innocrin PharmaceuticalPhase 1/Phase 2

See all Seviteronel clinical trials

Clinical Trial Summary for Seviteronel

Top disease conditions for Seviteronel
Top clinical trial sponsors for Seviteronel

See all Seviteronel clinical trials

Seviteronel Development Update and Market Projection

Last updated: September 16, 2026

Seviteronel, also known as VT-464 and INO-464, is an oral androgen-signaling inhibitor that targets CYP17 lyase and the androgen receptor. Its development has not produced an FDA approval, a commercial launch, or an active registrational program. The near-term commercial outlook is therefore effectively zero. A future market would require a new sponsor, fresh clinical evidence, and a successful Phase 3 program against established therapies such as abiraterone, enzalutamide, apalutamide, darolutamide, and taxane chemotherapy.

What is the current development status of seviteronel?

Seviteronel remains an unapproved investigational drug. Public clinical records show prior Phase 1 and Phase 2 development in metastatic castration-resistant prostate cancer and hormone-receptor-positive or androgen-receptor-positive breast cancer, but no completed Phase 3 program or FDA filing is evident in the public record.[1]

Item Current assessment
Generic name Seviteronel
Development codes VT-464, INO-464
Drug class Selective CYP17 lyase inhibitor and androgen-receptor antagonist
Original developer Viamet Pharmaceuticals
Later development sponsor Innocrin Pharmaceuticals
Primary indications studied Metastatic castration-resistant prostate cancer; androgen-receptor-positive breast cancer
FDA approval None identified
Commercial status Not marketed
Orange Book listing None identified
Phase 3 registrational evidence None identified
Current development posture Inactive or discontinued based on the absence of an active registrational program

Seviteronel was designed to inhibit androgen production while also blocking androgen-receptor signaling. The mechanism was intended to address tumors that progress after androgen-deprivation therapy, abiraterone, or other androgen-receptor pathway inhibitors.

The development rationale weakened as the prostate-cancer treatment market became more competitive and clinical data did not establish a sufficiently differentiated benefit. The breast-cancer program also did not produce evidence supporting late-stage development.

What mechanism and formulations were developed for seviteronel?

Seviteronel is an orally administered small molecule. Its principal pharmacologic targets are:

  1. CYP17 lyase, which reduces androgen synthesis.
  2. The androgen receptor, which suppresses androgen-mediated transcription.
  3. The androgen-signaling axis in tumors resistant to conventional hormonal therapy.

The compound was developed primarily as an oral tablet or capsule formulation for chronic outpatient dosing. Publicly available development records do not show an approved long-acting injectable, implant, transdermal system, or biologic version.

What formulations are protected by seviteronel patents?

Public patent disclosures associated with seviteronel and its developer describe small-molecule CYP17 lyase inhibitors, pharmaceutical compositions, treatment methods, and related salt or formulation concepts. The central commercial protection would have been expected to come from composition-of-matter claims, with later protection potentially directed to formulations, dosing regimens, combinations, and method-of-use claims.

Because seviteronel has no FDA-approved product, it has no FDA-recognized Orange Book patent estate. Any remaining patent rights would be assessed through national patent registers and the relevant assignees rather than through an Orange Book listing.

Patent protection is also less commercially valuable when clinical development is inactive. The key risks are not limited to patent expiry. They include lack of regulatory approval, inadequate clinical differentiation, manufacturing economics, and the possibility that a new sponsor would need to repeat or extend clinical studies.

When does seviteronel lose exclusivity?

Seviteronel does not have an FDA exclusivity date because it has never received FDA approval. It therefore has no approved-drug regulatory exclusivity period, no New Chemical Entity exclusivity clock, and no Orange Book-based generic-delay framework.

What is the patent expiration date for seviteronel?

A single definitive commercial patent expiration date cannot be inferred from the drug code alone. Seviteronel was covered through a patent family rather than one universally controlling patent. Relevant dates would depend on:

  • The jurisdiction.
  • The specific composition-of-matter patent.
  • Patent-term adjustment.
  • Patent-term extension.
  • Continuation or divisional patents.
  • Formulation and method-of-use claims.
  • Terminal disclaimers.
  • Post-grant amendments or litigation outcomes.

No FDA-approved reference product exists against which an Abbreviated New Drug Application applicant could certify in the ordinary Orange Book process. Patent expiry is therefore not the principal barrier to entry. The absence of a commercial product and the lack of an approved reference listed drug are more important.

What clinical trials tested seviteronel?

Seviteronel was evaluated in early and mid-stage studies involving heavily pretreated cancer populations.

Prostate cancer studies

The prostate-cancer program focused on men with metastatic castration-resistant disease, including patients who had received prior androgen-receptor pathway therapy. Studies evaluated seviteronel in settings involving prior abiraterone and/or enzalutamide exposure.

The clinical challenge was substantial. Patients with late-stage castration-resistant prostate cancer often have aggressive disease, multiple resistance mechanisms, and limited time for treatment. A drug that produces only modest prostate-specific antigen responses, without radiographic or survival improvement, is unlikely to support a broad commercial launch.

Breast cancer studies

Seviteronel was also studied in advanced breast cancer, particularly tumors selected for androgen-receptor expression or signaling. The program sought to exploit androgen dependence in a subset of breast cancers, including triple-negative disease.

The breast-cancer opportunity was biologically plausible but commercially narrower than the prostate-cancer opportunity. It also faced competition from antibody-drug conjugates, immunotherapies, PARP inhibitors, CDK4/6 inhibitors, and other biomarker-directed treatments.

What is the FDA regulatory status of seviteronel?

The FDA has not approved seviteronel for prostate cancer, breast cancer, or any other indication. No approved label, prescribing information, Risk Evaluation and Mitigation Strategy, or postmarketing commitment exists.

The absence of approval means:

  • No FDA-recognized indication.
  • No approved dosage.
  • No validated manufacturing specification for a marketed product.
  • No Orange Book reference listing.
  • No Hatch-Waxman exclusivity period.
  • No established reimbursement standard.
  • No FDA-approved combination regimen.

A future sponsor would likely need to establish a new clinical and regulatory package. Prior Phase 2 data could support program design, but those data would not substitute for adequate and well-controlled trials required for approval.

Which companies are challenging seviteronel?

No active generic or biosimilar challenge is publicly relevant because seviteronel is not an approved marketed product.

Is there biosimilar risk for seviteronel?

No. Seviteronel is a small molecule, not a biologic. The applicable future competition would come from generic small-molecule versions, not biosimilars. Generic entry would require an approved reference product and an FDA pathway such as an ANDA, neither of which currently exists.

If seviteronel were revived and approved, generic risk would depend on the surviving composition, formulation, and method-of-use patents, as well as any regulatory exclusivity awarded with approval.

What patent litigation affects seviteronel?

No major public patent litigation has established a market-blocking or market-opening event for seviteronel. The more material issue is the absence of a commercial launch and the lack of an active late-stage program.

Are there Paragraph IV challenges for seviteronel?

No meaningful Paragraph IV challenge is publicly associated with seviteronel. A Paragraph IV certification generally arises when a generic applicant references an Orange Book-listed drug and asserts that listed patents are invalid, unenforceable, or not infringed. Seviteronel has no FDA-approved reference product or Orange Book listing, so the conventional Paragraph IV framework is not currently operative.

How strong is the patent estate for seviteronel?

The estate appears strategically meaningful at the discovery and development stages but commercially unproven.

Patent category Likely role Commercial assessment
Composition of matter Protects the active molecule and related compounds Potentially strongest claim type, subject to expiration and validity
Pharmaceutical composition Covers drug-product formulations and excipients Useful but usually narrower than composition claims
Method of treatment Covers use in prostate or breast cancer Vulnerable to claim-scope and induced-infringement issues
Combination therapy Covers use with androgen-deprivation therapy or other agents May support lifecycle management
Manufacturing process Protects synthesis, purification, or solid-state form Could raise supply-chain barriers but rarely blocks all generic development

The practical patent strength is reduced by the development status. A patent estate cannot generate meaningful product revenue without an approved indication and a commercial supply chain.

What market could seviteronel address?

The largest theoretical market is metastatic castration-resistant prostate cancer. The commercial opportunity would be narrower than the total prostate-cancer market because treatment would likely target patients with prior exposure to androgen-receptor pathway inhibitors.

Potential positioning could include:

  • Post-abiraterone treatment.
  • Post-enzalutamide treatment.
  • Patients with persistent androgen-receptor dependence.
  • Patients unsuitable for or unwilling to receive chemotherapy.
  • Biomarker-selected tumors with androgen-receptor signaling.
  • Combination therapy with androgen-deprivation treatment.

The breast-cancer opportunity would likely require biomarker selection, such as androgen-receptor-positive or molecularly defined disease. That could produce a higher response rate in a selected population but would limit the number of eligible patients.

What is the market projection for seviteronel?

The base-case market projection is no commercial revenue in the near term because the drug lacks approval, a registrational program, and a confirmed development sponsor.

Scenario-based commercial projection

Scenario Probability-weighted commercial interpretation Potential peak annual sales
Base case: development remains inactive No launch $0
Revival with modest Phase 2 success Regional or niche launch possible $50 million to $200 million
Successful prostate-cancer approval Specialist oncology product $200 million to $500 million
Broad prostate-cancer positioning with strong survival data Competitive global product $500 million to $1 billion or more
Breast-cancer approval only Biomarker-restricted opportunity $50 million to $250 million

These are strategic scenario ranges, not reported company guidance or consensus estimates. The high-end scenario requires a clinically meaningful advantage over established hormonal agents and chemotherapy, a tolerable safety profile, and a development strategy capable of overcoming the drug's long inactive period.

A revived seviteronel program would face direct competition from:

  • Abiraterone plus prednisone.
  • Enzalutamide.
  • Apalutamide.
  • Darolutamide.
  • Docetaxel and cabazitaxel.
  • Lutetium-177 PSMA-directed therapy.
  • PARP inhibitors in homologous-recombination-deficient tumors.
  • Radiopharmaceuticals and emerging androgen-receptor degraders.

The strongest commercial positioning would require either a biomarker-defined responder population or demonstrated activity after failure of multiple androgen-receptor pathway agents.

How does seviteronel compare with abiraterone and enzalutamide?

Attribute Seviteronel Abiraterone Enzalutamide
Regulatory status Investigational, unapproved FDA-approved FDA-approved
Main target CYP17 lyase and androgen receptor CYP17 enzyme Androgen receptor
Market status No commercial product Established commercial product Established commercial product
Generic competition Not currently relevant Present or emerging by jurisdiction Present or emerging by jurisdiction
Clinical positioning Experimental salvage or biomarker-selected use Prostate cancer across approved settings Prostate cancer across approved settings
Commercial risk Development and regulatory risk Generic erosion and competition Generic erosion and competition

Seviteronel's theoretical advantage was dual pathway suppression. Its disadvantage was the lack of clinical evidence showing that this mechanism translated into superior survival, durable disease control, or meaningful benefit after prior androgen-receptor therapy.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are likely manageable for a small-molecule oral product if the active ingredient can be produced at commercial scale with acceptable purity and solid-state control. The more important barriers would be:

  • Re-establishing qualified drug-substance and drug-product suppliers.
  • Reconstructing analytical methods and release specifications.
  • Confirming formulation stability.
  • Demonstrating process consistency.
  • Identifying any active polymorph, salt, or crystalline-form claims.
  • Preserving trade secrets related to synthesis and purification.
  • Funding new clinical development.

The drug's small-molecule nature reduces the complexity associated with biologic manufacturing. It also means that, if approved, generic manufacturers could eventually develop alternative synthetic routes unless valid and enforceable process or composition claims remained in force.

What licensing deals involve seviteronel?

Seviteronel originated with Viamet Pharmaceuticals and was subsequently associated with Innocrin Pharmaceuticals. Public records identify licensing and development arrangements around the compound, but there is no publicly established commercial partnership comparable to the large oncology licensing transactions associated with approved products.

The absence of a current commercial license or active large-pharma development program is consistent with the drug's inactive status. Any future transaction would likely be structured as an asset acquisition, regional license, or option agreement contingent on new proof-of-concept data.

Key Takeaways

  • Seviteronel is an unapproved oral CYP17 lyase inhibitor and androgen-receptor antagonist.
  • Development reached Phase 2 in prostate cancer and breast cancer but has not advanced to an evident Phase 3 registrational program.
  • No FDA approval, Orange Book listing, approved reference product, or Paragraph IV dispute is currently relevant.
  • Biosimilar competition does not apply because seviteronel is a small molecule.
  • The near-term commercial forecast is zero without a new sponsor and a clinical restart.
  • A revived prostate-cancer program could support a niche product, but it would face entrenched competition from abiraterone, enzalutamide, darolutamide, apalutamide, taxanes, radiopharmaceuticals, and targeted therapies.
  • Patent rights may remain relevant at the asset level, but regulatory and clinical execution are greater barriers than generic entry.
  • A commercially meaningful launch would require new efficacy data, a differentiated target population, and a defensible patent or regulatory-exclusivity position.

FAQs

Is seviteronel available by prescription?

No. Seviteronel is not an FDA-approved or commercially marketed prescription drug.

Was seviteronel withdrawn from clinical development?

Public records show no active registrational program. Its prior clinical development appears inactive or discontinued, although individual historical studies may have different completion or termination statuses.[1]

Can seviteronel replace abiraterone or enzalutamide?

No. Seviteronel has no approved indication and has not established clinical superiority or noninferiority to either drug.

Does seviteronel have orphan-drug designation?

No FDA orphan-drug approval or commercially relevant orphan exclusivity is identified for seviteronel in the public FDA record.

Could seviteronel be revived for androgen-receptor-positive breast cancer?

A revival is scientifically possible, but it would require new sponsor funding, updated clinical evidence, biomarker strategy, manufacturing readiness, and regulatory agreement on the development path.

References

  1. ClinicalTrials.gov. (n.d.). Search results for seviteronel, VT-464, and INO-464 clinical studies. U.S. National Library of Medicine. https://clinicaltrials.gov/search?term=seviteronel
  2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
  3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
  4. National Cancer Institute. (n.d.). Drug dictionary: Seviteronel. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/seviteronel
  5. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.